Tag : Astellas Pharma Inc

Healthcare Quality, Patient Safety & Policy

Astellas, Evopoint Ink Deal for CLDN18.2 ADC XNW27011

PR Newswire
by PR Newswire0146
Agreement grants Astellas exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 XNW27011 has demonstrated encouraging monotherapy efficacy in an ongoing Phase 1/2 study...
Clinical Research, Pharma & Healthcare Financing

Pfizer and Astellas’ PADCEV® + KEYTRUDA® Shows Long-Term Efficacy

Business Wire
by Business Wire0220
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phase 3...